HSE Delays & Low Awareness Leave Many Without Nuvaxovid Access During COVID Wave

In a letter to Dr. Henry, Long Covid Advocacy Ireland (LCAI) expresses strong dissatisfaction with the HSE’s ongoing lack of access and public awareness around non-mRNA COVID-19 vaccines like Nuvaxovid during the 13th COVID wave. LCAI challenges claims of “low public demand” when neither the public, GPs, nor pharmacists are properly informed about the protein-subunit option, and highlights past pre-Christmas rollout delays alongside confusing claims about sourcing doses from America despite Sanofi having an operational presence in Ireland. Calling out unnecessary barriers for immunocompromised people and others who cannot or choose not to take mRNA vaccines, LCAI urges the HSE to establish a clear domestic supply route with Sanofi Ireland, issue guidance to GPs and pharmacists, and proactively communicate non-mRNA vaccine availability.

Leave a Reply